Overview

* SI-BONE ( SIBN ) Q3 revenue grows 20.6% yr/yr, beating analyst expectations

* Net loss for Q3 improves by 30.6% to $4.6 mln

* Adjusted EBITDA turns positive at $2.3 mln in Q3

Outlook

* SI-BONE ( SIBN ) expects 2025 revenue between $198 mln and $200 mln, up from prior $195 mln to $198 mln

* Company estimates full-year 2025 gross margin to be ~79.5%

Result Drivers

* U.S. PROCEDURE DEMAND - Strong underlying demand for procedures drove U.S. revenue growth

* PHYSICIAN GROWTH - 27% increase in active U.S. physicians contributed to revenue growth

* TORQ LAUNCH - International revenue growth supported by TORQ launch in Europe

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $48.66 $46.70

Revenue mln mln (8

Analysts

)

Q3 Net -$4.57

Income mln

Q3 Gross 79.80%

Margin

Q3 Basic -$0.11

EPS

Q3 $44.23

Operatin mln

g

Expenses

Q3 -$5.38

Operatin mln

g income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for SI-BONE Inc ( SIBN ) is $25.00, about 36.9% above its November 7 closing price of $15.77

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)